20.11.2026

"New Oral GLP-1 Medication for Weight Loss Approved"

Health Canada has authorized a new GLP-1 medication for weight loss that is a pill taken every day, rather than weekly injections

Health Canada has recently authorized a new medication, Foundayo, developed by Eli Lilly, for weight loss. Unlike other treatments, this new GLP-1 medication comes in pill form, offering a convenient option for patients who prefer daily oral intake over weekly injections.

Foundayo is approved for use in adults who are struggling with obesity, as well as those who are overweight and have at least one related health condition, such as high blood pressure or sleep apnea. Additionally, this medication is recognized for its ability to aid in the management of Type 2 diabetes, making it a versatile treatment option.

In the realm of GLP-1 medications, Eli Lilly is also the manufacturer behind injectable drugs such as Mounjaro and Zepbound. These injectables contain tirzepatide, a dual-action agent that interacts with both GLP-1 and GIP receptors to facilitate insulin production and regulate hunger. In comparison, competitor Novo Nordisk produces injectable options like Ozempic and Wegovy, which utilize semaglutide and primarily target GLP-1 receptors.

The emergence of GLP-1 medications has significantly transformed weight-loss treatment paradigms, with experts noting that many patients may prefer the oral format of Foundayo over traditional injectable forms. Currently, another oral GLP-1 product, Novo Nordisk's Rybelsus, is available in Canada; however, it is limited to managing Type 2 diabetes and is not approved for weight loss.

Foundayo's active ingredient, orforglipron, is noteworthy for being a non-peptide GLP-1 receptor agonist. Dr. Ehud Ur, an endocrinologist based in Vancouver, pointed out that because orforglipron is a smaller molecule compared to peptide-based drugs like semaglutide and tirzepatide, it can be effectively administered orally without undergoing degradation in the digestive system. He further stated that orforglipron appears to be equally effective, if not more so, than its counterparts for achieving weight loss.

As with other GLP-1 medications, both injectable and oral forms, the side effects commonly reported include gastrointestinal disturbances such as nausea and vomiting. Dr. Ur mentioned that his decision to prescribe Foundayo will depend on individual patient considerations, particularly as he awaits further clinical trial results to clarify whether orforglipron provides cardiovascular benefits similar to those observed with semaglutide and tirzepatide.

The approval for Foundayo was granted by Health Canada on November 13, and Eli Lilly anticipates that the medication will be available for purchase in pharmacies starting in January. There is also the possibility of a second oral GLP-1 weight-loss option entering the Canadian market soon, as Novo Nordisk's Wegovy pill awaits Health Canada's approval.

Both Foundayo and the Wegovy pill are already approved and available in the United States. Despite the large peptide structure of semaglutide, Novo Nordisk has developed a method to produce Wegovy in pill form by incorporating an additive known as salcaprozate sodium (SNAC). This ingredient plays a critical role in protecting the peptide from digestive enzymes, allowing it to successfully pass through the stomach lining and into the bloodstream once ingested.